New Drug Gains Approval For Treating X-Linked Hypophosphatemia in the U.S.
source: pixabay.com

New Drug Gains Approval For Treating X-Linked Hypophosphatemia in the U.S.

According to a story from globenewswire.com, the pharmaceutical companies Ultragenyx and Kyowa Kirin recently issued an announcement that the U.S. FDA has granted approval to their new treatment Crysvita (burosumab-twza).…

Continue Reading New Drug Gains Approval For Treating X-Linked Hypophosphatemia in the U.S.
Combination Treatment is Dramatically Improving Outcomes for Mantle Cell Lymphoma Patients
source: pixabay.com

Combination Treatment is Dramatically Improving Outcomes for Mantle Cell Lymphoma Patients

According to a story from adc.net.au, an innovative new cancer treatment regimen is responsible for doubling survival rates for patients with certain types of rare, difficult-to-treat blood cancers. This combination…

Continue Reading Combination Treatment is Dramatically Improving Outcomes for Mantle Cell Lymphoma Patients
Patients with Ankylosing Spondylitis Don’t Fully Trust Biosimilars
source: pixabay.com

Patients with Ankylosing Spondylitis Don’t Fully Trust Biosimilars

According to a story from ankylosingspondylitisnews.com, a significant proportion of patients stopped taking a biosimilar for infliximab within six months of transitioning to the new medication. This suggests that the…

Continue Reading Patients with Ankylosing Spondylitis Don’t Fully Trust Biosimilars
New Campaign Encourages Idiopathic Pulmonary Fibrosis Patients to Keep Exercising
Source: Pixabay.com

New Campaign Encourages Idiopathic Pulmonary Fibrosis Patients to Keep Exercising

According to a story from The Irish Times, a new campaign is encouraging people with the rare lung condition idiopathic pulmonary fibrosis to keep exercising. The campaign is centered around…

Continue Reading New Campaign Encourages Idiopathic Pulmonary Fibrosis Patients to Keep Exercising
Company Continues to Back an Experimental Therapy for Duchenne Muscular Dystrophy Despite Clinical Hold
source: pixabay.com

Company Continues to Back an Experimental Therapy for Duchenne Muscular Dystrophy Despite Clinical Hold

According to a story from genengnews.com, the pharmaceutical company Solid Biosciences is pledging to continue developing its investigation drug candidate SGT-001 for Duchenne muscular dystrophy. This is despite its clinical…

Continue Reading Company Continues to Back an Experimental Therapy for Duchenne Muscular Dystrophy Despite Clinical Hold
A Physician Sees the Patient Perspective When Getting Treated For Primary Periodic Paralysis
source: pixabay.com

A Physician Sees the Patient Perspective When Getting Treated For Primary Periodic Paralysis

According to a story from Neurology Advisor, a retired physician experienced the challenges of being a rare disease patient first hand after being diagnosed with primary periodic paralysis thanks to…

Continue Reading A Physician Sees the Patient Perspective When Getting Treated For Primary Periodic Paralysis